Evidence map›Paper›PMID 39093709›Full record

ArticleNeuropsychopharmacology reports2024

Effect of A118G (rs1799971) single-nucleotide polymorphism of the μ-opioid receptor OPRM1 gene on intraoperative remifentanil requirements in Japanese women undergoing laparoscopic gynecological surgery.

Ruying Zou, Daisuke Nishizawa, Rie Inoue, Junko Hasegawa, Yuko Ebata, Kyoko Nakayama, Atsuko Hara, Hiroyuki Sumikura, Mari Kitade, Masakazu Hayashida and 2 more

Abstract read
In one paragraph

Article in Neuropsychopharmacology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ruying ZouDepartment of Anesthesiology and Pain Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Daisuke NishizawaAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Rie InoueDepartment of Anesthesiology and Pain Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Junko HasegawaAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Yuko EbataAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Kyoko NakayamaAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Atsuko HaraDepartment of Anesthesiology and Pain Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Hiroyuki SumikuraDepartment of Anesthesiology and Pain Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Mari KitadeDepartment of Obstetrics and Gynecology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Masakazu HayashidaDepartment of Anesthesiology and Pain Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Kazutaka IkedaAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.ORCID 0000-0001-8342-0278
Izumi KawagoeDepartment of Anesthesiology and Pain Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Funding

Japan Agency for Medical Research and Development JP19dk0307071Japan Agency for Medical Research and Development JP19ek0610011Japan Society for the Promotion of Science 17H04324Japan Society for the Promotion of Science 17K08970Japan Society for the Promotion of Science 18K08829Japan Society for the Promotion of Science 20K09259Japan Society for the Promotion of Science 21H03028Japan Society for the Promotion of Science 22790518Japan Society for the Promotion of Science 23390377Japan Society for the Promotion of Science 23K21457Japan Society for the Promotion of Science 24790544Japan Society for the Promotion of Science 26293347Japan Society for the Promotion of Science JP22H04922 [AdAMS]Ministry of Health, Labour and Welfare H26-Kakushintekigan-ippan-060
6 · The paper itself

Abstract

aimAbundant data are available on the effect of the A118G (rs1799971) single-nucleotide polymorphism (SNP) of the μ-opioid receptor OPRM1 gene on morphine and fentanyl requirements for pain control. However, data on the effect of this SNP on intraoperative remifentanil requirements remain limited. We investigated the effect of this SNP on intraoperative remifentanil requirements.

methodsWe investigated 333 Japanese women, aged 21-69 years, who underwent laparoscopic gynecological surgery for benign gynecological disease under total intravenous anesthesia at Juntendo University Hospital. Average infusion rates of propofol and remifentanil during anesthesia and the average bispectral index (BIS) during surgery were recorded. Associations among genotypes of the A118G and phenotypes were examined with the Mann-Whitney U test.

resultsThe average propofol infusion rate was not different between patients with different genotypes. The average remifentanil infusion rate was significantly higher in patients with the AG or GG genotype than the AA genotype (p = 0.028). The average intraoperative BIS was significantly higher in patients with the GG genotype than the AA or AG genotype (p = 0.039).

conclusionsThe G allele of the A118G SNP was associated with higher intraoperative remifentanil requirements and higher intraoperative BIS values but was not associated with propofol requirements. Given that remifentanil and propofol act synergistically on the BIS, these results suggest that the G allele of the A118G SNP is associated with lower effects of remifentanil in achieving adequate intraoperative analgesia and in potentiating the sedative effect of propofol on the BIS.

Indexed as

Analgesics, OpioidGynecologic Surgical ProceduresLaparoscopyPolymorphism, Single NucleotideReceptors, Opioid, muRemifentanilAdultAgedAnesthetics, IntravenousEast Asian PeopleFemaleGenotypeHumansJapanMiddle AgedPiperidinesAnalgesics, OpioidAnesthetics, IntravenousOPRM1 protein, humanPiperidinesPropofolReceptors, Opioid, muRemifentanilbispectral indexlaparoscopic gynecologic surgerymu‐opioid receptor generemifentanilsingle‐nucleotide polymorphism

Identifiers

PMID39093709
PMCPMC11544447

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.